UNCY - Unicycive Therapeutics Inc
IEX Last Trade
0.3317
-0.011 -3.346%
Share volume: 1,183,547
Last Updated: Fri 30 Aug 2024 09:59:25 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.34
-0.01
-3.24%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-12 | 2022-08-15 | 2022-11-14 | 2023-03-31 | 2023-05-16 | 2023-08-14 | 2023-11-14 | 2024-03-28 | |
| Assets | |||||||||
| Total Assets | 15.760 M | 18.744 M | 10.177 M | 2.818 M | 27.202 M | 22.883 M | 19.442 M | 14.191 M | |
| Current Assets | 15.464 M | 18.411 M | 9.962 M | 2.644 M | 26.184 M | 21.930 M | 18.569 M | 13.399 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.844 M | 1.832 M | 2.952 M | 2.189 M | 1.852 M | 3.112 M | 4.224 M | 3.698 M | |
| Short Term Investments | 1.844 M | 1.832 M | 2.952 M | 2.189 M | 1.852 M | 3.112 M | 4.224 M | 3.698 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 13.620 M | 16.579 M | 7.010 M | 455.000 K | 24.332 M | 18.818 M | 14.345 M | 9.701 M | |
| Total Non-current Assets | 296.000 K | 333.000 K | 215.000 K | 174.000 K | 1.018 M | 953.000 K | 873.000 K | 792.000 K | |
| Property Plant Equipment | 28.000 K | 28.000 K | 24.000 K | 22.000 K | 21.000 K | 30.000 K | 28.000 K | 26.000 K | |
| Other Assets | 268.000 K | 305.000 K | 191.000 K | 152.000 K | 997.000 K | 923.000 K | 845.000 K | 766.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 15.760 M | 18.744 M | 10.177 M | 2.818 M | 27.202 M | 22.883 M | 19.442 M | 14.191 M | |
| Total liabilities | 2.516 M | 2.260 M | 5.551 M | 3.284 M | 16.685 M | 16.053 M | 16.052 M | 18.000 M | |
| Total current liabilities | 2.402 M | 2.105 M | 5.522 M | 3.284 M | 15.970 M | 15.419 M | 15.456 M | 17.534 M | |
| Accounts Payable | 589.000 K | 742.000 K | 2.292 M | 892.000 K | 790.000 K | 503.000 K | 1.084 M | 839.000 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 44.000 K | 0.000 | |
| Current long term debt | 155.000 K | 151.000 K | 165.000 K | 155.000 K | 276.000 K | 303.000 K | 314.000 K | 327.000 K | |
| Long term debt | 114.000 K | 155.000 K | 29.000 K | 0.000 | 715.000 K | 634.000 K | 552.000 K | 466.000 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 44.000 K | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 13.244 M | 16.484 M | 4.626 M | -466.000 K | 10.517 M | 6.830 M | 3.390 M | -3.809 M | |
| Common stock | 15.005 M | 15.029 M | 15.062 M | 15.133 M | 15.232 M | 15.235 M | 32.633 M | 35.057 M | |
| Retained earnings | -19.476 M | -15.939 M | -28.669 M | -33.997 M | -48.572 M | -52.410 M | -56.743 M | -64.541 M |